dehydroepiandrosterone has been researched along with Dysthymic Disorder in 2 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Dysthymic Disorder: Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. (DSM-IV)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the efficacy of the adrenal androgen, dehydroepiandrosterone, in the treatment of midlife-onset dysthymia." | 9.09 | Dehydroepiandrosterone treatment of midlife dysthymia. ( Adams, LF; Bloch, M; Danaceau, MA; Rubinow, DR; Schmidt, PJ, 1999) |
| "This study evaluated the efficacy of the adrenal androgen, dehydroepiandrosterone, in the treatment of midlife-onset dysthymia." | 5.09 | Dehydroepiandrosterone treatment of midlife dysthymia. ( Adams, LF; Bloch, M; Danaceau, MA; Rubinow, DR; Schmidt, PJ, 1999) |
| " DHEA dosing was flexible (100-400 mg/day)." | 2.72 | Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. ( Ferrando, SJ; McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rabkin, JG | 1 |
| McElhiney, MC | 1 |
| Rabkin, R | 1 |
| McGrath, PJ | 1 |
| Ferrando, SJ | 1 |
| Bloch, M | 1 |
| Schmidt, PJ | 1 |
| Danaceau, MA | 1 |
| Adams, LF | 1 |
| Rubinow, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dehydroepiandrosterone Treatment of Mid-Life-Related Mood Disorders in Women and Men[NCT00001487] | Phase 2 | 60 participants | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for dehydroepiandrosterone and Dysthymic Disorder
| Article | Year |
|---|---|
Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Adolescent; Adult; Aged; Dehydroepiandro | 2006 |
Dehydroepiandrosterone treatment of midlife dysthymia.
Topics: Adaptation, Psychological; Adjuvants, Immunologic; Adult; Affect; Cognition; Cross-Over Studies; Cro | 1999 |